(Q37738539)

22 August 2017

1 reference

title

Tyrosine kinase inhibitors: the first decade (English)

1 reference

22 August 2017

3

Jorge Cortes

1 reference

22 August 2017

Meetu Agrawal

1

1 reference

22 August 2017

Ravin J Garg

series ordinal

2

1 reference

22 August 2017

Alfonso Quintás-Cardama

series ordinal

4

1 reference

22 August 2017

publication date

1 April 2010

1 reference

Current hematologic malignancy reports

22 August 2017

published in

1 reference

22 August 2017

volume

5

1 reference

22 August 2017

issue

2

1 reference

22 August 2017

page(s)

70-80

1 reference

High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy

22 August 2017

cites work

1 reference

12 December 2020

Molecular biology of bcr-abl1-positive chronic myeloid leukemia

1 reference

12 December 2020

Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R).

1 reference

12 December 2020

Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency

1 reference

12 December 2020

Chronic myeloid leukemia: molecular monitoring in clinical practice

1 reference

12 December 2020

VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo

1 reference

12 December 2020

Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia

1 reference

12 December 2020

Resistance to imatinib mesylate in chronic myeloid leukaemia

1 reference

12 December 2020

Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia

1 reference

12 December 2020

Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia

1 reference

12 December 2020

Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial

1 reference

12 December 2020

Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimizati

1 reference

12 December 2020

Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy

1 reference

12 December 2020

European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor.

1 reference

12 December 2020

Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia

1 reference

12 December 2020

Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: does it really matter?

1 reference

12 December 2020

Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase.

1 reference

12 December 2020

Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative.

1 reference

12 December 2020

INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity.

1 reference

12 December 2020

Flying under the radar: the new wave of BCR-ABL inhibitors

1 reference

12 December 2020

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

1 reference

12 December 2020

Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets

1 reference

12 December 2020

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

1 reference

12 December 2020

Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis

1 reference

12 December 2020

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

12 December 2020

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

1 reference

12 December 2020

Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase

1 reference

12 December 2020

Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis

1 reference

12 December 2020

Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy

1 reference

12 December 2020

Survival advantage from imatinib compared with the combination interferon- plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials

1 reference

12 December 2020

10.1007/S11899-010-0045-Y

Identifiers

DOI

1 reference

22 August 2017

1 reference